Immunohistochemical subtypes of the breast cancer in the ultrasound and clinical aspect – literature review

1Wojciechowska U, Didkowska J: Illnesses and deaths from malignant neoplasms in Poland. National Registry Cancer, National Oncology Institute im. Maria Skłodowska-Curie – National Research Institute. Available at: http://onkologia.org.pl/raporty/WojciechowskaUDidkowskaJIllnesses and deaths from malignant neoplasms in Poland. National Registry Cancer, National Oncology Institute imMaria Skłodowska-Curie – National Research InstituteAvailable athttp://onkologia.org.pl/raporty/Search in Google Scholar

2Jassem J, Krzakowski M, Bobek-Billewicz B et al.: Breast cancer. Oncol Clin Pract 2020; 16(5): 207–260.JassemJKrzakowskiMBobek-BillewiczBet alBreast cancerOncol Clin Pract2020165207260Search in Google Scholar

3Dobruch-Sobczak K: Współczesna ultrasonografia piersi. Medycyna po Dyplomie 2021; 30(9): 36–42.Dobruch-SobczakKWspółczesna ultrasonografia piersiMedycyna po Dyplomie20213093642Search in Google Scholar

4Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S et al.: Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 2014; 19: 608–615.BonottoMGerratanaLPolettoEDriolPGiangrecoMRussoSet alMeasures of outcome in metastatic breast cancer: insights from a real-world scenarioOncologist20141960861510.1634/theoncologist.2014-0002404167824794159Search in Google Scholar

5Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA et al.: Annual Report to the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst 2015; 107: djv048.KohlerBAShermanRLHowladerNJemalARyersonABHenryKAet alAnnual Report to the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and StateJ Natl Cancer Inst2015107djv04810.1093/jnci/djv048460355125825511Search in Google Scholar

6Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750–2767.LehmannBDBauerJAChenXSandersMEChakravarthyABShyrYet alIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest20111212750276710.1172/JCI45014312743521633166Search in Google Scholar

7Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y et al.: Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One 2016; 11: e0157368.LehmannBDJovanovićBChenXEstradaMVJohnsonKNShyrYet alRefinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selectionPLoS One201611e015736810.1371/journal.pone.0157368491105127310713Search in Google Scholar

8Li Y, Yang D, Chen P, Yin X, Sun J, Li H et al.: Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis. Aging (Albany NY) 2019; 11: 6286–6311.LiYYangDChenPYinXSunJLiHet alEfficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysisAging (Albany NY)2019116286631110.18632/aging.102188673840431446432Search in Google Scholar

9Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P et al.: Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 2018; 24: 628–637.TuttAToveyHCheangMCUKernaghanSKilburnLGazinskaPet alCarboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialNat Med20182462863710.1038/s41591-018-0009-7637206729713086Search in Google Scholar

10Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A et al.: Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017; 3: 1378–1385.HahnenELedererBHaukeJLoiblSKröberSSchneeweissAet alGermline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto Randomized Clinical TrialJAMA Oncol201731378138510.1001/jamaoncol.2017.1007571050828715532Search in Google Scholar

11Masuda N, Lee SJ, Ohtani S, Im Y-H, Lee E-S, Yokota I et al.: Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376: 2147–2159.MasudaNLeeSJOhtaniSImY-HLeeE-SYokotaIet alAdjuvant capecitabine for breast cancer after preoperative chemotherapyN Engl J Med20173762147215910.1056/NEJMoa161264528564564Search in Google Scholar

12Cui M, Wang H, Yao X, Zhang D, Xie Y, Cui R et al.: Circulating MicroRNAs in cancer: potential and challenge. Front Genet 2019; 10: 626.CuiMWangHYaoXZhangDXieYCuiRet alCirculating MicroRNAs in cancer: potential and challengeFront Genet20191062610.3389/fgene.2019.00626665685631379918Search in Google Scholar

13Yang Q, Liu HY, Liu D, Song YQ: Ultrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtypes. Asian Pac J Cancer Prev 2015; 16: 3229–3232.YangQLiuHYLiuDSongYQUltrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtypesAsian Pac J Cancer Prev2015163229323210.7314/APJCP.2015.16.8.322925921124Search in Google Scholar

14Li Z, Tian J, Wang X, Wang Y, Zhang L, Jing H et al.: Differences in multi-modal ultrasound imaging between triple negative and non-triple negative breast cancer. Ultrasound Med Biol 2016; 42: 882–890.LiZTianJWangXWangYZhangLJingHet alDifferences in multi-modal ultrasound imaging between triple negative and non-triple negative breast cancerUltrasound Med Biol20164288289010.1016/j.ultrasmedbio.2015.12.003Search in Google Scholar

15Li J-W, Zhang K, Shi Z-T, Zhang X, Xie J, Liu J-Y et al.: Author correction: Triple-negative invasive breast carcinoma: the association between the sonographic appearances with clinicopathological feature. Sci Rep 2020 10: 4468.LiJ-WZhangKShiZ-TZhangXXieJLiuJ-Yet alAuthor correction: Triple-negative invasive breast carcinoma: the association between the sonographic appearances with clinicopathological featureSci Rep202010446810.1038/s41598-020-61260-3Search in Google Scholar

16Dogan BE, Gonzalez-Angulo AM, Gilcrease M, Dryden MJ, Yang WT: Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol 2010; 194: 1160–1166.DoganBEGonzalez-AnguloAMGilcreaseMDrydenMJYangWTMultimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRIAJR Am J Roentgenol20101941160116610.2214/AJR.09.2355Search in Google Scholar

17Ko ES, Lee BH, Kim H-A, Noh W-C, Kim MS, Lee S-A: Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol 2010; 20: 1111–1117.KoESLeeBHKimH-ANohW-CKimMSLeeS-ATriple-negative breast cancer: correlation between imaging and pathological findingsEur Radiol2010201111111710.1007/s00330-009-1656-3Search in Google Scholar

18Yeo SH, Kim GR, Lee SH, Moon WK: Comparison of ultrasound elastography and color doppler ultrasonography for distinguishing small triple-negative breast cancer from fibroadenoma. J Ultrasound Med 2018; 37: 2135–2146.YeoSHKimGRLeeSHMoonWKComparison of ultrasound elastography and color doppler ultrasonography for distinguishing small triple-negative breast cancer from fibroadenomaJ Ultrasound Med2018372135214610.1002/jum.14564Search in Google Scholar

19Zhang L, Li J, Xiao Y, Cui H, Du G, Wang Y et al.: Identifying ultrasound and clinical features of breast cancer molecular subtypes by ensemble decision. Sci Rep 2015; 5: 11085.ZhangLLiJXiaoYCuiHDuGWangYet alIdentifying ultrasound and clinical features of breast cancer molecular subtypes by ensemble decisionSci Rep201551108510.1038/srep11085Search in Google Scholar

20Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ et al.: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346–352.CurtisCShahSPChinS-FTurashviliGRuedaOMDunningMJet alThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature201248634635210.1038/nature10983Search in Google Scholar

21Zhou BP, Hung MC: Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 2003; 30: 38–48.ZhouBPHungMCDysregulation of cellular signaling by HER2/neu in breast cancerSemin Oncol200330384810.1053/j.seminoncol.2003.08.006Search in Google Scholar

22Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E et al.: 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017; 389: 1195–1205.CameronDPiccart-GebhartMJGelberRDProcterMGoldhirschAde AzambujaEet al11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialLancet20173891195120510.1016/S0140-6736(16)32616-2Search in Google Scholar

23Perez EA, Romond EH, Suman VJ, Jeong J-H, Sledge G, Geter Jr CE et al.: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014; 32: 3744–3752.PerezEARomondEHSumanVJJeongJ-HSledgeGGeterJr CEet alTrastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831J Clin Oncol2014323744375210.1200/JCO.2014.55.5730422680525332249Search in Google Scholar

24Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al.: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273–1283.SlamonDEiermannWRobertNPienkowskiTMartinMPressMet alAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med20113651273128310.1056/NEJMoa0910383Search in Google Scholar

25Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK et al.: Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372: 134–141.TolaneySMBarryWTDangCTYardleyDAMoyBMarcomPKet alAdjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancerN Engl J Med201537213414110.1056/NEJMoa1406281Search in Google Scholar

26Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25–32.GianniLPienkowskiTImY-HRomanLTsengL-MLiuM-Cet alEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol201213253210.1016/S1470-2045(11)70336-9Search in Google Scholar

27Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al.: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164–172.CortazarPZhangLUntchMMehtaKCostantinoJPWolmarkNet alPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet201438416417210.1016/S0140-6736(13)62422-8Search in Google Scholar

28Swain SM, Macharia H, Cortes J, Dang C, Gianni L, Hurvitz S et al.: Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: a retrospective exploratory analysis. Cancer Res 2020; 80: P1-18-01.SwainSMMachariaHCortesJDangCGianniLHurvitzSet alRisk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: a retrospective exploratory analysisCancer Res202080P118-0110.1158/1538-7445.SABCS19-P1-18-01Search in Google Scholar

29von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M et al.: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019; 380: 617–628.vonMinckwitz GHuangCSManoMSLoiblSMamounasEPUntchMet alTrastuzumab emtansine for residual invasive HER2-positive breast cancerN Engl J Med201938061762810.1056/NEJMoa181401730516102Search in Google Scholar

30Algazzar MA, Elsayed E, Alhanafy AM, Mousa WA: Breast cancer imaging features as a predictor of the hormonal receptor status, HER2neu expression and molecular subtype. Egypt J Radiol Nuclear Med 2020; 51: 93.AlgazzarMAElsayedEAlhanafyAMMousaWABreast cancer imaging features as a predictor of the hormonal receptor status, HER2neu expression and molecular subtypeEgypt J Radiol Nuclear Med2020519310.1186/s43055-020-00210-5Search in Google Scholar

31Sun SS, Zhang B, Zhao HM, Cao XC: Association between mammographic features and clinicopathological characteristics in invasive ductal carcinoma of breast cancer. Mol Clin Oncol 2014; 2: 623–629.SunSSZhangBZhaoHMCaoXCAssociation between mammographic features and clinicopathological characteristics in invasive ductal carcinoma of breast cancerMol Clin Oncol2014262362910.3892/mco.2014.297405157024940507Search in Google Scholar

32Boisserie-Lacroix M, Hurtevent-Labrot G, Ferron S, Lippa N, Bonnefoi H, Mac Grogan G: Correlation between imaging and molecular classification of breast cancers. Diagn Interv Imaging 2013; 94: 1069–1080.Boisserie-LacroixMHurtevent-LabrotGFerronSLippaNBonnefoiHMacGrogan GCorrelation between imaging and molecular classification of breast cancersDiagn Interv Imaging2013941069108010.1016/j.diii.2013.04.01023867597Search in Google Scholar

33Kim SH, Seo BK, Lee J, Kim SJ, Cho KR, Lee KY et al.: Correlation of ultrasound findings with histology, tumor grade, and biological markers in breast cancer. Acta Oncol. 2008; 47: 1531–1538.KimSHSeoBKLeeJKimSJChoKRLeeKYet alCorrelation of ultrasound findings with histology, tumor grade, and biological markers in breast cancerActa Oncol2008471531153810.1080/0284186080197141318607848Search in Google Scholar

34Cho N: Molecular subtypes and imaging phenotypes of breast cancer. Ultrasonography 2016; 35: 281–288.ChoNMolecular subtypes and imaging phenotypes of breast cancerUltrasonography20163528128810.14366/usg.16030504013627599892Search in Google Scholar

35Elias SG, Adams A, Wisner DJ, Esserman L, van’t Veer LJ, Mali WPTM et al.: Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014; 23: 1464–1483.EliasSGAdamsAWisnerDJEssermanLvan’t VeerLJMaliWPTMet alImaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysisCancer Epidemiol Biomarkers Prev2014231464148310.1158/1055-9965.EPI-13-117024807204Search in Google Scholar

36Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG et al.: US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014; 106.HowladerNAltekruseSFLiCIChenVWClarkeCARiesLAGet alUS incidence of breast cancer subtypes defined by joint hormone receptor and HER2 statusJ Natl Cancer Inst201410610.1093/jnci/dju055458055224777111Search in Google Scholar

37Weigelt B, Baehner FL, Reis-Filho JS: The contribution of gene expression profiling to breast cancer classification, prognostication, and prediction: a retrospective of the last decade. J Pathol 2010; 220: 263–280.WeigeltBBaehnerFLReis-FilhoJSThe contribution of gene expression profiling to breast cancer classification, prognostication, and prediction: a retrospective of the last decadeJ Pathol201022026328010.1002/path.264819927298Search in Google Scholar

38Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer J-U et al.: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005; 23: 5108–5116.SmithIEDowsettMEbbsSRDixonJMSkeneABlohmerJ-Uet alNeoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trialJ Clin Oncol2005235108511610.1200/JCO.2005.04.00515998903Search in Google Scholar

39Eiermann W, Paepke S, Appfelstaedt J, Llombart- Cussac A, Eremin J, Vinholes J et al.: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527–1532.EiermannWPaepkeSAppfelstaedtJLlombart-Cussac AEreminJVinholesJet alPreoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyAnn Oncol2001121527153210.1023/A:1013128213451Search in Google Scholar

40Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW et al.: Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 2013; 137: 465–470.EggemannHIgnatovASmithBJAltmannUvon MinckwitzGRöhlFWet alAdjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patientsBreast Cancer Res Treat201313746547010.1007/s10549-012-2355-323224235Search in Google Scholar

41Sousa B, Moser E, Cardoso F: An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol 2013; 717: 71–83.SousaBMoserECardosoFAn update on male breast cancer and future directions for research and treatmentEur J Pharmacol2013717718310.1016/j.ejphar.2013.03.03723545364Search in Google Scholar

42Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P et al.: Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol 2018; 29: 405–417.CardosoFBartlettJMSSlaetsLvan DeurzenCHMvan Leeuwen-StokEPorterPet alCharacterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramAnn Oncol20182940541710.1093/annonc/mdx651583407729092024Search in Google Scholar

43Azim HA Jr, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M et al.: Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol 2013; 24: 647–654.AzimHA JrMichielsSZagouriFDelalogeSFilipitsMNamerMet alUtility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementAnn Oncol20132464765410.1093/annonc/mds645626787823337633Search in Google Scholar

44Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A: Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012; 38: 698–707.ErolesPBoschAPérez-FidalgoJALluchAMolecular biology in breast cancer: Intrinsic subtypes and signaling pathwaysCancer Treat Rev20123869870710.1016/j.ctrv.2011.11.00522178455Search in Google Scholar

45Ades F, Zardavas D, Bozovic-Spasojevic, Pugliano L, Fumagalli D, de Azambuja E et al.: Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J. Clin. Oncol 2014; 32: 2794–2803.AdesFZardavasDBozovic-SpasojevicPuglianoLFumagalliDdeAzambuja Eet alLuminal B breast cancer: molecular characterization, clinical management, and future perspectivesJ. Clin. Oncol2014322794280310.1200/JCO.2013.54.187025049332Search in Google Scholar

46Taneja S, Evans AJ, Rakha EA, Green AR, Ball G, Ellis IO: The mammographic correlations of a new immunohistochemical classification of invasive breast cancer. Clin Radiol 2008; 63: 1228–1235.TanejaSEvansAJRakhaEAGreenARBallGEllisIOThe mammographic correlations of a new immunohistochemical classification of invasive breast cancerClin Radiol2008631228123510.1016/j.crad.2008.06.00618929040Search in Google Scholar

47Stavros A: Ultrasound of solid breast nodules: distinguishing benign from malignant. In: Breast ultrasound. Lippincott Williams & Wilkins, Philadelphia, 2004: 459–460, 488.StavrosAUltrasound of solid breast nodules: distinguishing benign from malignant. In: Breast ultrasoundLippincott Williams & Wilkins, Philadelphia2004459–460488Search in Google Scholar

48Liu H, Wan J, Xu G, Xiang L-H, Fang Y, Ding S-S et al.: Conventional US and 2-D shear wave elastography of virtual touch tissue imaging quantification: correlation with immunohistochemical subtypes of breast cancer. Ultrasound Med Biol 2019; 45: 2612–2622.LiuHWanJXuGXiangL-HFangYDingS-Set alConventional US and 2-D shear wave elastography of virtual touch tissue imaging quantification: correlation with immunohistochemical subtypes of breast cancerUltrasound Med Biol2019452612262210.1016/j.ultrasmedbio.2019.06.42131371128Search in Google Scholar